Document Classification

Section Type: METHODS

Text: From February 1994 to February 2000, 190 patients were randomly assigned between either four cycles of BEP (bleomycin 30 mg d1, d8, d15 ; etoposide 100 mg/m (2) d1-5 ; cisplatin 20 mg/m (2) d1-5) or four to six alternating cycles of CISCA/VB (cyclophosphamide 400 mg/m (2) d1-2, doxorubicin 35 mg/m (2) d1-2, cisplatin 100 mg/m (2) d3/vinblastine 2. 5 mg/m (2) d1-5, bleomycin 25 mg/m (2) d1-5).